Effect of complete response on outcome following autologous stem cell transplantation for myeloma

Bone Marrow Transplantation

Volumn 26, Issue 9, 2000, Pages 979-983

  Rajkumar, S V ^a   Fonseca, R ^a   Dispenzieri, A ^a   Lacy, M Q ^a   Witzig, T E ^a   Lust, J A ^a   Larson, D ^a   Therneau, T M ^a   Kyle, R A ^a   Litzow, M R ^a   Greipp, P R ^a   Gertz, M A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Complete response; Multiple myeloma; Prognosis; Transplantation

Indexed keywords

DEXAMETHASONE; DOXORUBICIN; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOTRANSPLANTATION; CANCER SURVIVAL; CELL LABELING; CONTROLLED STUDY; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PLASMA CELL; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 0033764023     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702640     Document Type: Article

References (23)

1. Multiple myeloma
2. Cancer statistics, 2000
3. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: An overview of 6.633 patients from 27 randomized trials
4. Intensive treatment strategies in myeloma
5. The treatment of multiple myeloma
6. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: Results of Eastern Cooperative Oncology Group Study E2479
7. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome
8. Biology and therapy of multiple myeloma in 1996
9. Total therapy with tandem transplants for newly diagnosed multiple myeloma
10. Response level and survival after conventional chemotherapy for multiple myeloma: A Finnish Leukaemia group study
11. The effect of complete response (CR) on survival in an ECOG phase III trial for multiple myeloma
12. Prognostic factors in multiple myeloma
13. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma
14. Culturing and robotic harvesting of bone marrow, lymph nodes, peripheral blood, fibroblasts, and solid tumors with in situ techniques
15. Peripheral blood B cell labeling indices are a measure of disease activity in patients with monoclonal gammopathies
16. Nonparametric estimation from incomplete observations
17. Regression models and life tables
18. Analysis of survival by tumor response
19. Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants
20. Standard therapy versus autologous transplantation in multiple myeloma
21. Limited value of myeloablative therapy for late multiple myeloma
22. Early versus late high dose therapy (HDT) and autologous peripheral blood stem cell transplantation in multiple myeloma (MM): Results of a prospective randomized trial